Autosomal Dominant Polycystic Kidney clinical trials

Explore recruiting autosomal dominant polycystic kidney clinical trials.

Recruiting autosomal dominant polycystic kidney studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Autosomal Dominant Polycystic Kidney trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Spain, Portugal, Germany, Netherlands, France, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi- centre, 2 parallel arms randomized controlled trial

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Safety of rotigotine in patients with autosomal dominant polycystic kidney disease - ETERNAL-PKD

France

Therapeutic exploratory (Phase II) EU CTIS Study details

HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT)

Spain, France, Netherlands, Belgium, Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Autosomal Dominant Polycystic Kidney trials by city

Autosomal Dominant Polycystic Kidney in Toronto Autosomal Dominant Polycystic Kidney in Vancouver Autosomal Dominant Polycystic Kidney in Montreal Autosomal Dominant Polycystic Kidney in Calgary Autosomal Dominant Polycystic Kidney in Edmonton Autosomal Dominant Polycystic Kidney in Ottawa Autosomal Dominant Polycystic Kidney in Winnipeg Autosomal Dominant Polycystic Kidney in Quebec City Autosomal Dominant Polycystic Kidney in Hamilton Autosomal Dominant Polycystic Kidney in Kitchener Autosomal Dominant Polycystic Kidney in London Autosomal Dominant Polycystic Kidney in Halifax Autosomal Dominant Polycystic Kidney in New York Autosomal Dominant Polycystic Kidney in Los Angeles Autosomal Dominant Polycystic Kidney in Chicago Autosomal Dominant Polycystic Kidney in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease